Gossamer Bio, Inc. announced that its stockholders have approved the potential issuance of common stock related to a Securities Purchase Agreement dated August 20, 2026. The approval was required under Nasdaq listing rules because the total number of shares to be issued could exceed 20% of the company's outstanding common stock. This approval allows the company to proceed with the financing arrangement.
Key Details
- Event: Approval was granted at a special stockholder meeting on October 27, 2026, to satisfy Nasdaq Listing Rules 5635(c) and 5635(d).
- Agreement: The share issuance is pursuant to a Securities Purchase Agreement from August 20, 2026, which includes the issuance of common stock, pre-funded warrants, and FDA approval warrants.
- Vote Results: The proposal was approved with 2,808,000 votes for, 37,814 against, and 29,441 abstentions.